Antibody-drug conjugates (ADCs) are a class of targeted therapeutics that utilize the specificity of antibodies to selectively deliver highly potent cytotoxins to target cells. Although recent years have witnessed significant interest in ADCs, problems remain with the standard linkage chemistries used for cytotoxin-antibody bioconjugation. These typically (1) generate unstable constructs, which may lead to premature cytotoxin release, (2) often give a wide variance in drug-antibody ratios (DAR) and (3) have poor control of attachment location on the antibody, resulting in a variable pharmacokinetic profile.
Introduction
The emergence of biotherapeutics in recent decades has opened up vast new areas of research for the treatment of a range of grievous diseases, 1,2 with antibody-drug conjugates (ADCs) demonstrating considerable promise as anticancer agents.
3,4
ADCs utilize the impeccable cell-targeting ability of an antibody in combination with the highly potent nature of a cytotoxic payload to achieve cell-selective cytotoxicity 5 while overcoming the dose-limiting toxicity of classical non-targeted small molecule chemotherapy. 6, 7 There are currently four ADCs on the market [8] [9] [10] [11] and over 60 other ADCs in clinical trials. 12 However, current approaches for ADC production still have numerous shortcomings. Stability, drug-antibody ratio (DAR) and drug distribution have all been shown to be crucial to the efficacy, safety and overall pharmacological prole of ADCs and are strongly inuenced by the chemistry used to attach the linker to the antibody. Commonly employed nucleophilic bioconjugation at cysteine or lysine residues are pseudorandom: in theory, any of the targeted amino acids within the antibody can be modied. Consequently, there is a lack of selectivity, leading to the formation of ADCs which are heterogeneous in terms of the number of cytotoxin molecules incorporated (the DAR) and their locations on the antibody. Such constructs are associated with unreliable pharmacokinetic proles and therefore, a reduced pharmacological effect. [13] [14] [15] [16] [17] Maleimide conjugation to reduced antibody cysteine thiols has been extensively used in ADC development (Fig. 1a) . However, the formed succinimide thioether is inherently unstable in the body (due to a retroMichael reaction) which leads to premature dissociation of the payload from the antibody. 18, 19 The plasma stability of maleimide-based linkers has been increased by hydrolysis of the succinimide thioether ring through linker modications or antibody engineering. 20, 21 However, an inherently stable linker is preferential. The development of new ADC formats to enable site-selective antibody modication, including the incorporation of engineered cysteine residues 13 and unnatural amino acids 22, 23 into the antibody sequence and the use of various enzymatic processes, [24] [25] [26] have produced ADCs with precise DAR and dened attachment points. While effective, these methods are complicated and generally inefficient.
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Recently, disulde-bridging linkers have emerged for ADC production: a bis-reactive linker moiety undergoes reaction with both thiol residues derived from a reduced cysteine disulde bond, leading to covalent re-bridging of the protein. Such linkers are capable of generating ADCs with more precise DAR and drug distribution as well as reforming covalent bonds between the antibody chains. Signicant progress has been made in the eld with this class of linker by Baker, Caddick and Chudasama and their co-workers, amongst others.
27-36 Despite these impressive advances, new methods are still required for the production of stable and homogeneous ADCs from nonengineered antibodies. We sought to develop a new disulde bridging linker platform, which generated highly stable ADCs with precise DAR and drug distribution. Vinylpyridines have previously been used to modify proteins via cysteine conjugation. 37 Glythera has recently developed a monovinylpyridinebased linker platform for ADC construction with such conjugates demonstrating excellent stability (Fig. 1a) . We envisaged that divinyl-functionalised hetero-aryl linkers could be used to achieve cysteine re-bridging, generating inherently stable constructs whilst also achieving precise control of DAR and siteof-attachment with native antibodies.
Herein, we report upon our investigations in this area and development of a novel divinylpyrimidine (DVP) linker platform for cysteine-bridging bioconjugation with a range of proteins (Fig. 1b) . Model studies using the non-engineered trastuzumab antibody validate the utility of this linker platform for the generation of highly plasma-stable antibody constructs that incorporate different biologically relevant payloads in a robust and efficient manner. The utility of the DVP linker platform was also exemplied on other protein systems, exemplifying the capability of such linkers for a range of protein or peptide modication applications.
Results and discussion
We began our study by identifying the potential of a vinylheteroaryl scaffold for cysteine re-bridging. It was postulated that vinylpyridine bioconjugation would be too slow to enable efficient cross-linking but that replacement of the pyridine with a pyrimidine would enhance the reactivity to desirable levels by increasing the electron accepting capacity of the heteroaryl ring, without compromising the stability seen with vinylpyridine conjugates.
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To test this hypothesis, vinylpyrimidine 1 (prepared by a Suzuki-Miyaura cross-coupling, see ESI ‡) was reacted with Boc-Cys-OMe in a mixture of aqueous buffer and acetonitrile. Pleasingly, full conversion from 1 to conjugate 3 was achieved in 15 minutes, monitored by thin layer chromatography (TLC), under these bioconjugation compatible conditions (Fig. 2a) . A competition experiment involving the reaction of 1 with Boc-Cys-OMe and Boc-Lys-OMe at alkaline pH showed full conversion to the cysteine conjugate 3. No evidence of the lysine conjugate 5 was observed, even with an excess of vinylpyrimidine 1 present in the reaction ( Fig. 2b and ESI Fig. S1 ‡) . Similarly, 1 showed poor reactivity with tris(2-carboxyethyl) phosphine hydrochloride (TCEP), a commonly used reducing agent in cysteine bioconjugation (ESI Fig. S5 ‡) , demonstrating the capability of this scaffold for chemoselective cysteine conjugation. The stability of conjugate 3 under physiological conditions was investigated by incubation with an excess of reduced L-glutathione (GSH) in pH 7.4 buffer at 37 C. The stability was tracked via 1 H NMR and pleasingly, almost no degradation (<5%) was observed aer two weeks. In comparison, the corresponding maleimide conjugate 6 showed >50% conversion to the glutathione-maleimide conjugate aer two weeks under the same conditions ( Fig. 2c and S6 ‡). This suggested that vinylpyrimidine bioconjugation could indeed be used to generate conjugates that are stable under physiological conditions. Efforts then turned to the synthesis of divinylpyrimidine (DVP) linkers which contained reactive synthetic handles suitable for attachment of other modalities, such as drugs or uorophores. To this end, DVP linkers 7, 8 and 9 were synthesised in one, two and three steps, respectively (Fig. 2d , see ESI ‡ for synthetic details). The chemoselectivity of linkers 7, 8 and 9 was then conrmed in an analogous way to monovinylpyrimidine 1 (ESI Fig. S1-S4 ‡) . Subsequently, the stability of Boc-Cys-OMe modied 7, 8 and 9 in the presence of GSH was also demonstrated via 1 H NMR (ESI Fig. S6 ‡) .
We next sought to ascertain the reactivity of the DVP linkers in protein systems. RadA from Pyrococcus furiosus is a DNA recombinase enzyme that does not contain any cysteine residues. Through site-directed mutagenesis, a monomeric version was produced that contained two cysteine residues in close proximity in the tertiary structure (PfRadA-dCys, ESI Fig. S25 ‡) . Pleasingly, reduction of the mutant PfRadA with TCEP followed by the addition of linkers 7, 8 or 9 (15 equiv.) for 1 hour at 37 C yielded excellent conversion to the desired covalently re-bridged conjugates 10, 11 and 12, as detected by LC-MS ( conversion to the desired interchain-bridged conjugates 13-15 in 30 minutes using a slight excess of the linker (10 equiv.) ( Fig. 3b and ESI Fig. S10 -S13 ‡). Kinetic analysis of the bridging rate of 8 was conducted with 10 and 20 equivalents linker aer TCEP reduction. Strikingly, >90% re-bridging of the Fab chains was observed for both stoichiometries aer only 15 minutes (ESI Fig. S14 ‡) . To conrm the selectivity of the DVP linker platform for cysteine residues, 8 was incubated with unreduced trastuzumab Fab and no reaction was observed aer two hours at 37 C (ESI Fig. S23 ‡) . These results exemplify the potential for the DVP linker platform to serve as a general protein modi-cation tool for monomeric and multimeric proteins. Encouraged by earlier results, efforts shied toward modication of an IgG antibody. DVP linkers potentially enable modication of all four interchain disuldes in an IgG 1 , generating an ADC with denitive modication sites while giving a consistent DAR of four. 39 Trastuzumab mAb was reduced with TCEP, revealing eight free thiols as evidenced by LC-MS and Ellman's assay (ESI Fig. S15 ‡) . Subsequently, the reduced antibody was treated with a slight excess of 7, 8 or 9 (10 equiv. per disulde) for two hours at 37 C (Fig. 4a) . Removal of small molecule reagents by dialysis was followed by LC-MS, SDS-PAGE and RP-HPLC analysis. The fully re-bridged mAbs 16, 17 and 18 were evident by LC-MS, suggesting good conversion to the desired bioconjugates (ESI Fig. S15 , S17 and S18 ‡). Analysis by SDS-PAGE and RP-HPLC conrmed the presence of the correctly bridged antibodies (Fig. 4b and ESI Fig. S17 ‡) along with the 'half-antibody' formed by intrachain bridging of the hinge region heavy chain cysteines, an issue seen with other re-bridging linkers. 35, 40 A large number of conditions (reaction concentration, time, linker stoichiometry) were explored to avoid this 'half-antibody' formation, with little change observed (ESI Table S1 and Fig. S16 ‡) . Through this process, it was found that the reaction worked efficiently (90-95% conversion to the bridged bioconjugates) at low concentrations (<10 mM) and with a slight excess of DVP (2.5 equiv. per disulde). We postulate that the half-antibody conjugate remains useful as the modi-cation site and DAR are still controlled and the stability of the conjugate conferred through the DVP linker remains. Crucially, the light and heavy chains are always re-bridged efficiently, ensuring that the Fab region (the region that confers receptor specicity to the antibody) is covalently linked. In order to determine the effect of bridging on mAb aggregation, antibody conjugate 18 was analysed by size-exclusion chromatography (SEC). This showed identical aggregation levels observed for 18 and the unmodied mAb (Fig. 4c) .
It was anticipated that the synthetic handles present in DVP linkers would enable modular and divergent functionalisation, both before and aer DVP antibody conjugation. Terminal alkyne-functionalised DVP 8 was identied as a suitable candidate for post-conjugation modication, as copper-catalysed azide-alkyne cycloaddition (CuAAC) chemistry offers a well-established method for diverse functionalisation under physiologically relevant conditions.
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An azide-functionalised doxorubicin (19) was synthesised and reacted with 18 in the presence of CuSO 4 $5H 2 O, tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) and sodium ascorbate (Fig. 5a) . Gratifyingly, excellent conversion to triazole product 21 was observed by LC-MS. DAR analysis by UVvis spectroscopy also conrmed high conversion with a measured DAR of 4.0 (ESI Fig. S19 ‡) . With the aim of creating a potentially valuable cellular imaging agent, conjugate 18 was reacted with AlexaFluor™ 488 azide 20 under CuAAC conditions (Fig. 5a) . Similarly, excellent conversion was observed with a measured uorophore-antibody ratio (FAR) of 3.9 (ESI Fig. S20 ‡) .
Synthesis of 22 enabled assessment of the plasma stability of DVP bioconjugates. The uorescent antibody conjugate was incubated in human plasma supplemented with GSH at 37 C for two weeks. Pleasingly, in-gel uorescence and coomassie staining revealed almost no transfer of the AlexaFluor™ 488 label onto plasma proteins, or release of individual heavy or light chains from the antibody ( Fig. 5b and ESI Fig. 22 ‡) . This analysis conrms the stability assessment made on the small molecule model system that DVP linkers enable the generation of highly stable bioconjugates. Functionalisation before antibody conjugation was then examined using the highly potent dolastatin 10 analogue, monomethylauristatin E (MMAE) as a representative payload. A DVP-PEG 4 -MMAE linker-warhead, 24 was prepared from 8 and azide-functionalised MMAE (23) (see ESI ‡). Reaction of reduced trastuzumab with 24 (10 equiv. per disulde) proceeded with excellent conversion to 25 via LC-MS ( Fig. 5c and ESI Fig. S21 ‡) .
The biological effects of DVP-bridging were then investigated. Firstly, trastuzumab conjugates, 16-18 all demonstrated comparable affinities to the native antibody for the HER2 receptor via enzyme-linked immunosorbent assay (ELISA) (Fig. 6a) . Fluorescence-activated cell sorting (FACS) coupled with live individual cell imaging was next used to ensure that the DVP conjugation did not alter cellular recognition and selectivity. Fluorescent trastuzumab conjugate, 22 was incubated in both HER2-positive (SKBR3 and BT474) and HER2-negative (MCF7 and T47D) breast cancer cell lines. The cells were incubated at 37 C for 1 hour to allow antigen binding and complex internalisation, followed by washing with PBS to remove any unbound antibody. Subsequent FACS analysis revealed full labelling of both HER2-positive cell lines while only minor labelling was observed with HER2-negative cell lines (Fig. 6b) . Internalisation of the conjugate was observed in both HER2-positive cell types, with no internalisation visible in either HER2-negative cell line (Fig. 6c) , conrming that DVP bridging does not affect receptor specicity, affinity or complex internalisation. Finally, evaluation of the in vitro cytotoxicity of a therapeutically relevant ADC was undertaken. DVP-MMAE ADC 25, containing a non-cleavable linker was used to treat both HER2-positive (SKBR3 and BT474) and HER2-negative (MCF7 and T47D) cell lines. Cytotoxicity was only observed in the HER2-positive cell lines (Fig. 6f and ESI Fig. S24 ‡) , demonstrating that DVP linkers do not affect the cell-killing ability of MMAE, enabling the use of these linkers for the delivery of auristatin payloads with non-cleavable linkers. In contrast to the specic cytotoxicity observed with our ADC, treatment of the same cell lines with free MMAE resulted in high levels of cytotoxicity in both HER2-positive and HER2-negative cell lines (Fig. 6d) . Furthermore, incubation of unmodied trastuzumab with these cell lines did not cause signicant cytotoxicity (Fig. 6e) . 
Conclusion
In conclusion, we have developed a novel DVP linker platform for bioconjugation through the covalent re-bridging of cysteine residues generated by the reduction of native disulde bonds. Model studies using the trastuzumab antibody validate the utility of this linker platform for the efficient generation of highly plasma-stable antibody constructs from non-engineered antibodies. We have shown that this technology can be used to introduce different biologically relevant payloads, in an efficient and site-selective manner with control over DAR, either before or aer bioconjugation, without recourse to any other additional processes. Furthermore, the conjugation platform utilizes a reaction that is orthogonal to other biocompatible reactions (such as the CuAAC), enabling their use in tandem with one another. The modied antibodies maintained their cellular specicity and receptor affinity, and a DVP-ADC demonstrated exquisite potency and selectivity for its target cells, while having little effect on the mechanism of action of its auristatin payload. In addition, the DVP linkers showed excellent cysteine re-bridging of monomeric and dimeric proteins, enabling their use for general protein modication, 42 protein stabilisation 43, 44 or the development of other biotherapeutics such as stapled peptides.
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